Effects of Immunonutrition on Biomarkers in Traumatic Brain Injury

Traumatic Brain Injury Clinical Trial

Official title:

Effects of Immunonutrition on Biomarkers in Traumatic Brain Injury Patients in Malaysia: a Prospective Randomized Controlled Trial.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03166449
• Other study ID #: 14-1430-23171.
• Status: Completed
• Phase: N/A
• First received: May 22, 2017
• Last updated: May 24, 2017
• Start date: July 1, 2014
• Est. completion date: July 31, 2015

Study information

• Verified date: May 2017
• Source: University of Malaya
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: Head injury is one of the top three diagnosis leading to intensive care unit (ICU) admission in Malaysia. There has been growing interest in using immunonutrition as a mode of modulating the inflammatory response to injury or infection with the aim of improving clinical outcome. The aim of the present study was to evaluate the effect of an immunonutrition on biomarkers (IL-6, glutathione, CRP, total protein and albumin) in traumatic brain injury patients.

Methods: Thirty six patients with head injury admitted to neurosurgical ICU in University Malaya Medical Centre were recruited for this study, over a 6-month period from July 2014 to January 2015. Patients were randomized to receive either an immunonutrition (Group A) or a standard (Group B) enteral feed. Levels of biomarkers were measured at day 1, 5 and 7 of enteral feeding.

Results: Patients in Group A showed significant reduction of IL-6 at day 5 (p<0.001) with concurrent rise in glutathione levels (p= 0.049). Patients in Group A also demonstrated a significant increase of total protein level at the end of the study (day 7).

Conclusion: These findings indicate the potential of immunonutrition reducing cytokines and increasing antioxidant indices in patients with TBI. However, further studies incorporating patient outcomes are needed to determine its overall clinical benefits.

Description:

Introduction:

In 2014, injury ranked fifth as the most common cause of hospitalisation in Malaysia, with 86% of major trauma patients sustaining injuries to head and neck. It is known that injuries to the brain is among the most likely to result in death and disability. Therefore, it was unsurprising when the Malaysian Registry of Intensive Care reported head injury as one of the top three diagnosis leading to intensive care unit (ICU) admissions with an in-hospital mortality rate of 22.1%. In addition to causing a significant problem in Malaysia, injury related mortality and morbidity also affects countries worldwide and is expected to be a major cause of death and disability by the year 2030.

This study aims to evaluate the effect of a specific immunonutrition, Neomune, on biomarkers (cytokines, acute phase serum proteins and antioxidants) in traumatic brain injury patients. This immune enhancing enteral feed contains arginine, glutamine and omega-3 fatty acid.

Methods:

This study and its protocol was approved by the Medical Ethics Committee University Malaya Medical Center (MEC ID NO: 20143-15). Written informed consent was obtained from patient's next of kin.

A prospective randomized controlled trial in patients with head injury comparing two high energy protein enteral formula; Neomune (manufactured by Thai Otsuka Pharmaceutical Co., Ltd., Thailand) and Fresubin® HP (manufactured by Fresenius Kabi, Bod Hamburg, Germany) was conducted. Fresubin® HP energy is the standard enteral feeding used in neurosurgical ICU patients in University Malaya Medical Centre. Neomune was chosen to study its immune-modulating effects.

Patients receiving Neomune were classified as Group A (n=18), whereas those receiving Fresubin® HP energy as Group B (n=18). Neomune is enriched with arginine, glutamine and omega-3 fatty acid.

Subject recruitment criteria:

Thirty six patients with head injury admitted to neurosurgical ICU, University Malaya Medical Centre were recruited for this study, over a 6-month period from July 2014 to January 2015. Patient's inclusion criteria were a) age between 15-78 years old, b) admission within 48 hours of post traumatic event, c) moderate to severe head injury (Glasgow Coma Scale 3-12) and, d) requiring enteral nutrition. Exclusion criteria were a) history of uncontrolled diabetes mellitus, b) history of renal or liver dysfunction, c) severe sepsis with multi organ failure and d) history of significant abdominal or chest injuries requiring major surgery.

Feeding protocol:

Eligible patients were randomized into receiving either Neomune (Group A) or Fresubin® HP energy (Group B) using a computerized random number generator. Fresubin® HP energy is a premixed formula with an energy of 1.5kcal/ml. Neomune formula comes in powder form and thus was prepared to reach a concentration of 1.5kcal/ml in order to make it comparable for the trial.

Enteral feeding was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines [6]. All feeding were introduced via nasogastric tube and carried out using infusion pump. Enteral feeding was commenced at an initial rate of 20 ml/h, and increased by 20 ml/h every 6 hours until target calorie was reached, provided that there was no significant gastric residual volume (<300 mL). The target calorie for each patient was determined by the clinician working alongside the dietitian using Harris Benedict equation which measures Resting Energy Expenditure (REE). This was further corrected 140% of REE based on studies done on traumatic brain injured patients and nutrition guidelines published by the BTF, the American Association of Neurological Surgeons, and the Joint Section on Neurotrauma and Critical Care. Patients going for scheduled surgery are kept nil by mouth 6 hours prior surgery. Feeding interruption are also kept to a minimal if patients are undergoing procedures, extubation or imaging.

Data collection:

Venous blood was withdrawn from patients at day 1, 5 and 7 of enteral nutrition to measure the levels of interleukin-6 (IL-6), glutathione, C-reactive protein (CRP), total protein and albumin. The concentration of IL-6 and glutathione were determined by ELISA (R&D Systems, Minneapolis, USA) according to manufacturer's protocol. Prealbumin was not included as a nutritional biomarker in this study because this test is not available in our standard laboratory test. Furthermore, we were also limited by resource constraint. All measured outcomes were compared between Group A and Group B.

Sample size analysis:

The sample size for this study was calculated based on a similar study done previously on immune enhancing nutrition in traumatic brain injury by Painter et al.

Statistical analysis The data were analysed using SPSS (Statistical Package for the Social Sciences) software version 20.0. Paired t-test was used to compare the concentration of cytokines, acute phase serum proteins and antioxidants between day 1, 5 and 7 after the administration of enteral feeding. Independent sample t-test was used to compare continuous data which include cytokines, acute phase serum proteins and antioxidant levels between Group A and Group B. Statistical significance was predetermined at p < 0.05.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: July 31, 2015
• Est. primary completion date: July 31, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 15 Years to 78 Years

Eligibility

Inclusion Criteria:

• Admission within 48 hours of post traumatic event

• Moderate to severe head injury (Glasgow Coma Scale 3-12)

• Requires enteral nutrition.

Exclusion Criteria:

• Uncontrolled diabetes mellitus

• Renal or liver dysfunction

• Severe sepsis with multi organ failure

• History of significant abdominal or chest injuries requiring major surgery.

Related Conditions & MeSH terms

• Brain Injuries
• Immuno-Deficiency
• Immunologic Deficiency Syndromes
• Nutrient Deficiency
• Traumatic Brain Injury
• Wounds and Injuries

Intervention

Dietary Supplement:
• Neomune
Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
• Fresubin® HP energy
Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines

Locations

Country	Name	City	State
Malaysia	Anaesthesia Department, Faculty of Medicine, University Malaya	Kuala Lumpur	Federal Territory

Sponsors (1)

Lead Sponsor	Collaborator
University of Malaya

Country where clinical trial is conducted

Malaysia, 

References & Publications (1)

1. MOH: National trauma database January 2009 to December 2009 fourth report. 2011. 2. Health Facts 2015 [http://vlib.moh. gov.my/cms/ documentstorage/ com.tms.cms. document.Document_ef876440-a0188549-82a26f00 e6a36876/ KKM_ HEALTH _ FACTS _ 2015.pdf] 3.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Levels of biomarkers	Venous blood was withdrawn from patients to check levels of interleukin-6 (IL-6), glutathione, C-reactive protein (CRP)	Day 1 of enteral nutrition
Primary	Levels of biomarkers	Venous blood was withdrawn from patients to check levels of interleukin-6 (IL-6), glutathione, C-reactive protein (CRP)	Day 5 of enteral nutirtion
Primary	Levels of biomarkers	Venous blood was withdrawn from patients to check levels of interleukin-6 (IL-6), glutathione, C-reactive protein (CRP)	Day 7 of enteral nutirtion
Secondary	Levels of total protein and albumin	Venous blood was withdrawn from patients to check levels of total protein and albumin	Day 1, 5 and 7 of enteral nutrition